Skip to search boxSkip to navigationSkip to main content

Estrogen mitogenic action. II. Negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications

  • aUniversity of Texas Health Science Center at Houston
Research Output: Contribution to journal Article Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication metrics

Metrics

SciVal
Citations
9
SciVal
FWCI
0.22
SciVal
Author count
2
SciVal
Paper percentile
44
Scopus
Citations

PlumX, opens in new tab

Citations
9
Captures
18

Abstract

In an accompanying report (Moreno-Cuevas, J. E.; Sirbasku, D. A., In Vitro Cell. Dev. Biol.; 2000), we demonstrated 80-fold estrogen mitogenic effects with MTW9/PL2 rat mammary tumor cells in cultures supplemented with charcoal-dextran-treated serum. All sera tested contained an estrogen reversible inhibitor(s). The purpose of this report is to extend those observations to additional sex steroid-responsive human and rodent cell lines. Every line tested showed a biphasic response to hormone-depleted serum. Concentrations of ≤10% (v/v) promoted substantive growth. At higher concentrations, serum was progressively inhibitory. With estrogen receptor-positive (ER+) human breast cancer cells, rat pituitary tumor cells, and Syrian hamster kidney tumor cells, 50% (v/v) serum caused significant inhibition, which was reversed by very low physiologic concentrations of estrogens. This same pattern was observed with the steroid hormone-responsive LNCaP human prostatic carcinoma cells. Because steroid hormone mitogenic effects are now easily demonstrable using our new methods, the identification of positive results has nullified our original endocrine estromedin hypothesis. We also evaluated autocrine/paracrine growth factor models of estrogen-responsive growth. We asked if insulin-like growth factors I and II, insulin, transforming growth factor alpha, or epidermal growth factor substituted for the positive effects of estrogens. Growth factors did not reverse the serum-caused inhibition. We asked also if transforming growth factor beta (TGFβ) substituted for the serum-borne inhibitor. TGFβ did not substitute. Altogether, our results are most consistent with the concept of a unique serum-borne inhibitor as has been proposed in the estrocolyone model. However, the aspect of the estrocolyone model related to steroid hormone mechanism of action requires more evaluation. The effects of sex steroids at picomolar concentrations may reflect mediation via inhibitor 'activated' intracellular signaling pathways.

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 428-446 (19 pages)

Journal (Volume, Issue Number)

In Vitro Cellular and Developmental Biology - Animal (Volume 36, Issue 7)

Publication milestones

  • Published - 01/01/2000

Publication status

Published - 01/01/2000

ISSN

1071-2690

External Publication IDs

  • Scopus: 0033771691
  • PubMed: 11039494

Funding Details

We gratefully acknowledge the expert technical assistance of Ms. Tameka S. Smith, Mrs. Frances E. Leland, and Mrs. Lyudmila Zilberman. We also thank Ms. Emily Ballou for conducting human breast cancer cell growth assays. This research was supported by grants DAMD17-94-J-4473, DAMD17-98-1-8337, and DAMD17-99-1-9405 from the Department of Defense, U.S. Army Medical Research and Material Command, Breast Cancer Research Program, grants-in-aid from the Women's Fund for Health Education Research, Houston, Texas, a grant-in-aid from the Houston Texas Chapter of the Susan G. Komen Breast Cancer Foundation, and a grant-in-aid from the Cancer Federation, Banning, California.
FundersFunding numbers
Breast Cancer Research Program
-
DOD
-
MRMC
-
Women's Fund for Health Education and Research
-
SGK
-